Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Q3 2019 Earnings Conference Call - Final Transcript

Nov 12, 2019 • 05:00 pm ET


Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day and welcome to the Adamis Pharmaceuticals Corp. Third Quarter 2019 Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Dr. Dennis Carlo, President and CEO. Please go ahead, sir.

Dennis J. Carlo

Thank you. I'm Dennis Carlo, President and CEO of Adamis. Thank you for joining us today for the update, and welcome to our shareholders, analysts and anyone new to Adamis. Joining me today is our Chief Financial Officer, Rob Hopkins; our Chief Medical Officer, Dr. Ronald Moss; and our Chief Business Officer, David Marguglio.

Once again, the format for this call will consist of some remarks from management followed by an opportunity for some questions. This call is being webcast and will be available for replay in the Investors section of our website,

I will remind everyone that in today's call, we will make certain forward-looking statements regarding our business based on current expectations and current information. Those statements speak only as of today, and except as required by law, we do not assume any duty to update in the future any forward-looking statements made today. Of course, any forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements that we make today. Additional information concerning factors that could affect our business and financial results is included in our most recent annual report on Form 10-K with the Securities and Exchange Commission and in other subsequent filings that we make with the SEC. These are available at the SEC's website.

I would like now to transition into a discussion on ZIMHI. I know the topic is on everyone's mind and the regulatory status of our high-dose naloxone product, ZIMHI. As we suggested in the press release, November 4, the FDA delivered neither trick nor treat on October 31, the PDUFA date. I can honor for anything positive or negative from this but instead believe the agency is simply taking more time reviewing the file. The Company believes there is an immediate and obvious need for a high-dose naloxone product, and we remain committed to bringing ZIMHI to the market. Discussions with potential commercial partners for ZIMHI have been ongoing for several months, and I anticipate we will be able to announce our commercial plans in the very near future, either before or very soon after receiving approval.

Turning to SYMJEPI, on our second quarter investor call in August, I alluded to a few initiatives that Sandoz was undertaking to fully launch SYMJEPI. Since July, Sandoz has implemented several, however, their rollout has been slower than we anticipated. Critical to maximizing SYMJEPI's success is to visit the top prescribing allergists. We believe the Sandoz team is now targeting allergists and primary care physicians in their commercial efforts. Additionally, the website went live earlier this month and now supports the needs of the allergy patient with online resources like administration instructions, product brochure, doctor discussion guide and anaphylaxis action plan.